/
ARMP
$6.46-$0.94 (-12.70%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$271.7M
37M shares
52-week range
$1.85 – $16.34
32% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
XASE
CS
Borrow rate
2.50%
Moderate
Price (6 mo)
Loading chart…
Change+$2.49
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $823.0K | $4.5M | $5.5M | $4.5M | $5.2M | $4.9M |
| Cost of revenue | $1.4M | $1.4M | $14.4M | $20.0M | $35.0M | $972.0K | $34.4M | $1.5M |
| Gross profit | −$1.4M | −$1.4M | −$13.6M | −$15.5M | −$29.5M | $3.6M | −$29.3M | $3.4M |
| Gross margin | — | — | -1655.0% | -347.4% | -535.7% | 78.5% | -565.4% | 68.8% |
| R&D | $4.9M | $9.8M | $14.4M | $20.0M | $35.0M | $33.8M | $34.4M | $23.7M |
| Operating income | −$12.5M | −$19.1M | −$21.6M | −$23.8M | −$36.9M | −$40.9M | −$42.4M | −$31.2M |
| EBITDA | −$9.5M | −$17.2M | −$20.4M | −$21.9M | −$36.0M | −$65.4M | −$6.8M | −$155.7M |
| Net income | −$12.1M | −$19.5M | −$22.2M | −$23.2M | −$36.9M | −$69.0M | −$18.9M | −$173.8M |
| Net margin | — | — | -2695.1% | -517.5% | -670.2% | -1524.5% | -365.6% | -3544.0% |
| EPS (diluted) | -8.90 | -2.43 | -1.35 | -0.96 | -1.08 | -1.91 | -0.52 | -4.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-3.81 | $-4.42–$-3.19 | 1 |
| 2027 | $3M | $-1.34 | $-1.56–$-1.12 | 1 |
| 2028 | $56M | $-1.03 | $-1.20–$-0.86 | 1 |
| 2029 | $19M | $-0.59 | $-0.69–$-0.49 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Armata Pharmaceuticals, Inc. Common Stock
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
www.armatapharma.com- Employees
- 61
- IPO / List date
- May 27, 1994
- HQ
- LOS ANGELES, CA
Held by traders on TradeandTell
No one on the platform currently holds ARMP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 38,496 | $394.2K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2017-04-25 | 1-for-10reverse |
| 2011-07-07 | 100-for-1 |
Recent trades on TradeandTell
No one on the platform has traded ARMP yet.
